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Background: Cervical cancer is one of the most common types of cancer in women and is largely
attributable to persistent infection with high-oncogenic risk human papillomavirus (HPV) types.
Most HPV infections resolve spontaneously over 5 years, but, in a small fraction of women,
persistent infection with high-risk HPV results in cervical intraepithelial neoplasia (CIN) grade
2/3 and eventually cervical cancer.
Perspectives: Prophylactic vaccines based on HPV virus-like particles (VLPs) exploit the propen-
sity of the immune system to protect against HPV infection and resulting diseases, including
cancer. The quadrivalent (HPV types 6, 11, 16, 18) vaccine was 100% effective in preventing
HPV 16- and 18-related CIN 2/3 in young, HPV-naïve women and possessed similar efficacy
against anogenital warts and vaginal and vulvar neoplasias. HPV VLP vaccine-induced protection
is mediated by anti-HPV antibodies specific for conformational “neutralizing” determinants on
the HPV capsid.
Conclusions: The quadrivalent vaccine is highly immunogenic in human subjects; induces per-
sistent, high-titer, neutralizing antibodies for at least 5 years; and induces immune memory
responses. The quadrivalent HPV vaccine induces the greatest immune response in prepubertal
children (9 to 12 years). Long-term follow-up studies are planned through the Nordic cancer
registries to assess duration of HPV protection.
© 2007 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Introduction
Cervical cancer is one of the most common types of cancer
in women and is second only to breast cancer in over-
all cancer disease burden worldwide.1 Cervical cancer is
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almost exclusively (99.7%) attributable to persistent infec-
tion with high-oncogenic risk HPV types, especially HPV 16
and 18.2
The natural history of cervical cancer typically spans
a period of 15 to 20 years and involves a number of
critical steps (Figure 1), including infection of the normal
cervix with HPV; persistence of infection; progression to
precancer and ultimately development of invasive cancer.3
In immunocompetent individuals, development of HPV in-
fection and low-grade neoplasias is often reversible and
clearance of HPV infections and regression of precancer
often occurs.3 For example, >90% of incident and preva-
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Figure 1 Schematic representation of the natural history of the development of cervical cancer following exposure to high-risk HPV types
(e.g., HPV 16 and 18). HPV infects the normal cervix and undergoes a period of replication (5 weeks to 6 months). Most HPV infections
are subclinical and spontaneously resolve but they may manifest as low-grade dysplasia (cervical intraepithelial neoplasia [CIN] 1). In most
women, (98%) these lesions resolve without any clinical sequelae, but persistent high-risk HPV infection in a small fraction of women can
result in high-grade dysplasia (CIN 2/3) and eventually cervical cancer. Development of cervical cancer may take up to 20 years from
the time of HPV infection, during which time screening programs using the Pap test can be used to detect and direct the excision of
high-grade dysplastic lesions prior to cancer development. However, even with intensive Pap screening, approximately 1 in 60 women
with HPV infection develop cervical cancer. Several immunotherapies (e.g., encapsulated polynucleotide and fusion proteins) for cervical
cancer and preceding premalignant lesions are undergoing testing, but their potential clinical utility is unknown at this time. A quadrivalent
prophylactic vaccine that prevents infection with the most common high- and low-risk HPV types is the most effective means to reduce the
incidence not only of cervical cancer and cervical dysplasia, but also other genital neoplasias and warts.
lent HPV 16 infections in immunocompetent women resolve
within 5 years without any treatment, whereas clearance
is significantly impaired in subjects with HIV/AIDS.4,5 Acti-
vation of the host' s immune system thus appears to play a
central role in the resolution of HPV infection and conse-
quent HPV-associated disease of the cervix and anogenital
tract. While the exact nature of these immune responses
remains uncertain, there is evidence for contributions
from helper T cells, cytolytic T cells, and innate immune
mechanisms.6 However, since HPV is adept at evading
immunological detection through a variety of mechanisms,
the host' s immune response to HPV infection is generally
slow and weak.6
Prophylactic vaccines based on HPV virus-like particles
(VLPs) have been developed to exploit the propensity of
the immune system to protect against HPV infection. A
quadrivalent vaccine capable of preventing persistent HPV
infection with the most common high-risk types (HPV 16
and 18) and low risk types (HPV 6 and 11) represents
an effective means to reduce the incidence not only of
cervical cancer and cervical dysplasia, but also other gen-
ital neoplasias and warts. HPV VLP vaccines are highly
immunogenic in humans and induce high-titer HPV neu-
tralizing antibodies that persist for at least 5 years after
immunization.
This article will review the key components of the
immune response to HPV infection and characterize the
immune response to HPV VLP vaccine with respect to
the types, titers, and cross-reactivity of virus neutralizing
antibodies produced; the duration and potential correlates
of protection afforded after immunization; and the optimal
age for vaccination.
Natural immune responses to HPV infection
The natural first line of defense against any pathogen
is nonspecific resistance (innate immunity) provided by
the skin and mucosal surfaces, and non-epithelial re-
sponses, including interferon-α, cytokines, neutrophils,
and macrophages. The second line of defence (acquired
immunity) is specific for each pathogen and comprises
humoral immunity (mediated by antibodies which bind to
corresponding antigens and promote phagocytosis or lysis
via complement) and cell-mediated immunity (mediated by
cytotoxic T lymphocytes). Compared to other pathogens,
HPV is a poor immunogen due to several structural and
physiological characteristics: 1) HPV is a double-stranded
DNA virus with no RNA intermediate to invoke an innate im-
mune response; 2) during the early phase of infection, HPV
primarily produces non-secreted nucleoproteins that are
not cross-presented by infected cells; 3) most HPV proteins
are expressed at very low levels in the basal epithelium,
which is most accessible to the host immune system; 4)
HPV infects only cells of the skin and does not induce cell
death, a major activator of innate and adaptive immunity;
and 5) systemic HPV antigen presentation is limited.6 As a
result of these characteristics, HPV is effective in evading
immunological detection and invokes only a slow and weak
immune response by the host.
The IgG antibody response to incident HPV-16, -18, and
-6 infection is illustrated by a longitudinal study of 588
college women.7 This study showed that for all three HPV
types, the time course and magnitude of antibody response
to HPV L1 (the major capsid protein) varied considerably
among individuals, with some women showing a vigorous
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antibody response, while others had no detectable an-
tibody. The proportion of women who seroconverted for
HPV-16, -18, or -6 within 18 months was similar (59.5%,
54.1%, and 68.8%, respectively). Importantly, this study
demonstrates that HPV L1 capsid-specific antibody is not
a suitable diagnostic test for HPV infection (since many
women do not seroconvert after infection, even after 4
years) and also is an unlikely marker for regression.
Antibody responses to other types of HPV antigens (e.g.,
E1, E2, E6, and L2) in patients with acute or persistent
HPV infection or cervical cancer are minimal or absent.
However, antibodies to the non-structural antigen E7 have
been reported to develop at the onset of invasive cervical
cancer, suggesting that anti-E7 antibodies may be useful as
a marker for this malignancy.8
Cell-mediated immune responses to HPV infection have
also been intensively studied but are not completely
delineated.6 The importance of cell-mediated immunity in
controlling HPV infection is demonstrated by studies of pa-
tients with iatrogenic immunosuppression or HIV infection.9
For example, immunosuppressed renal transplant patients
have an increased incidence of HPV infection, cervical
squamous intraepithelial lesions, and genital warts.10- 12
Similarly, HIV-infected patients have an increased preva-
lence of HPV infections of the anogenital region, and the
resulting lesions persist longer than in people without HIV
infection.5,9 A recent study by de Jong and colleagues.13 of
patients with cervical cancer demonstrated that the HPV
16-specific CD4+ T-cell response to early HPV antigens (E2
and E6) was impaired, suggesting a possible explanation
for this cancer. The authors speculated that functional
CD4+ T-helper cells are critical for the immune response
necessary to avoid persistent HPV infection. Other studies
associated regression of HPV-induced warts with T-cell
(CD4) responses to HPV E6 in humans14; specific T-cell (CD4
and CD8) responses to E2 protein were also related to
outcome of canine oral papilloma virus (COPV) infections.15
In addition to cellular and humoral immunity, innate
(non-antigen specific) immunity may play a limited role in
host' s response to HPV infection. This assertion is based on
studies showing that agonists of Toll-like receptors (TLR),
a family of pathogen recognition receptors that mediate
innate immunity, promote regression of HPV infections in
a non-type-specific manner. These include TLR 9 agonists
(Personal Communication, Dr. Joel M. Palefsky, Univer-
sity of California, San Francisco, CA) and imiquimod, an
activator of TLR 7 and 8.16
Immune response to HPV prophylactic vaccine
The development of prophylactic vaccines against HPV over
the past 10 years followed the discovery of the technology
to produce VLPs, viral capsids that are devoid of the HPV
genome. Prior to the discovery of VLPs, development of
effective HPV vaccines was impeded by the fact that HPV
replication occurs only in differentiating epithelial cells,
and thus, conventional methods of continuous cell culture
to generate a killed or attenuated vaccine were not prac-
tical. In addition, an attenuated vaccine would potentially
expose healthy people to viral oncogenes and, thus, not
be acceptable. Recombinant DNA technology was used
to generate VLPs capable of mimicking the natural virus
and eliciting high-titers of virus neutralizing antibodies.
VLPs spontaneously assemble when the papillomavirus L1
protein (the most important structural component of the
viral coat) is overexpressed in several different cell types,
including mammalian, insect, and yeast cells.17- 22
Preclinical studies utilizing species-specific VLPs demon-
strated that vaccination protected from papillomavirus in-
fection and disease; that this protection correlated with
neutralizing antibodies; and that passive transfer of serum
containing these antibodies resulted in protection.20,21,23- 27
A study by Suzich and colleagues27 in dogs illustrates that
the protection against COPV following immunization with
COPV L1 VLP is mediated by COPV-specific antibodies.
Dogs vaccinated with COPV L1 VLP (but not control dogs
vaccinated with denatured VLPs or VLPs of other viruses)
developed high-titer COPV-specific IgG antibodies and
were completely protected from experimental challenge
with COPV. Naïve dogs infused with IgG from vaccinated
dogs were also protected against viral challenge.
Immunogenicity of HPV quadrivalent (types 6, 11,
16, 18) vaccine
HPV quadrivalent vaccine consists of a mixture of VLPs
formed from the L1 capsid protein of each of four HPV
types (6, 11, 16, and 18) formulated with a proprietary
aluminum adjuvant. It is usually administered intramus-
cularly in three doses (day 1, month 2, and month 6).28
Results from the combined Phase II/III studies show that
the quadrivalent vaccine was 100% efficacious at protect-
ing against HPV 16- and 18-related cervical intraepithelial
neoplasia (CIN) stage 2/3 (a precursor of invasive cervical
cancer) in HPV naïve women who received the three-dose
vaccination regimen (see article by Villa in this supplement
for detailed presentation of efficacy data).28 The quadriva-
lent vaccine also was efficacious in preventing anogenital
condylomata (warts), and vaginal and vulvar neoplasias in
HPV naïve volunteers.28
The 100% efficacy in protecting HPV-naïve subjects HPV
16- and 18-related CIN 2/3 prevented identification of an
immune correlate of long-term protection. Furthermore,
with no breakthrough HPV infections due to waning immu-
nity, the minimum protective anti-HPV antibody level could
not be ascertained. Nevertheless, antibody titer has been
used as a surrogate marker of protection in clinical trials,
particularly in adolescent populations in whom efficacy
studies are not feasible. Studies in 16- to 26-year-old ado-
lescents and young women and in 9- to 15-year-old girls and
boys have characterized the magnitude and duration of the
immune response to a quadrivalent HPV vaccine.28 These
measurements were made with a competitive luminex im-
munoassay (cLIA), in which monoclonal antibodies against
HPV-type specific, conformational, neutralizing epitopes
are employed.29
A recent study by Villa and colleagues illustrates the
rapid, potent, and sustained immunologic response to ad-
ministration of a quadrivalent vaccine targeting HPV 6, 11,
16, and 18 in sexually active young women who were at
risk for contracting HPV infections.30 As shown in Figure 2,
in the per protocol immunogenicity (PPI) cohort, which
comprised women who were naïve to these four HPV types
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Figure 2 Immunogenicity results from a double-blind, placebo-controlled, dose-ranging study of quadrivalent HPV (types 6, 11, 16, 18) L1
VLP vaccine in 1106 young women indicated that vaccine-induced anti-HPV 6, 11, 16, and 18 geometric mean titers (GMTs) peak at month 7
and gradually decrease to reach a plateau at Month 24. The per protocol immunogenicity (PPI) cohort comprised subjects who were naïve
to HPV 6, 11, 16, and 18 infection at baseline, were free of infection with the same vaccine HPV type, and who received all three vaccine
doses. cLIA = competitive luminex immunoassay, GMT = geometric mean titer. , per-protocol subjects; •, baseline HPV type seropositive
and polymerase chain reaction-negative subjects (placebo group); , per-protocol placebo. Adapted from Villa LL et al.30
at baseline, vaccination induced a marked immune re-
sponse, beginning approximately 1 month after the initial
dose, peaking at approximately month 7, and thereafter
declining to a stable plateau for 2.5 years after the last
vaccine dose. All women in the PPI cohort developed
anti-HPV 6, 11, 16, and 18 antibodies and the magnitude of
the antibody response was approximately 10- to 100-fold
greater than that seen in women in the placebo group
who were vaccine-type seropositive (i.e., had prior natural
infection) at baseline.
In a subsequent 2-year extension of this study (involving
a subset of 241 women followed for an additional 2 years),
the immune response to quadrivalent vaccine was found to
be greater than or equal to that observed during natural
infection and was maintained through 5 years (Table 1).30,31
At month 7, patients receiving quadrivalent vaccine had
anti-HPV geometric mean titers (GMTs) that were sub-
stantially higher than those in placebo-recipients with a
previous history of natural HPV infection. At month 60, the
vaccine-induced anti-HPV GMTs remained at or above those
measured in placebo-treated women who had mounted
a natural immune response to HPV infection. Computer
modeling of the response to an HPV 16 L1 vaccine suggests
that the HPV antibody will persist for 12 years to near
life-long.32
Anamnestic response to quadrivalent vaccine
A key additional finding of the Villa study30 was that immu-
nization with quadrivalent vaccine induced an anamnestic
response, a hallmark of vaccines that induce memory
and provide long-term protection. Thus,administration of
quadrivalent vaccine to women who had detectable HPV
antibodies at enrollment (i.e., prior infection) tended to
result in higher anti-HPV responses that those induced in
vaccine recipients who were naïve to the relevant HPV
type at baseline. Indeed, two months after the first dose of
vaccine, vaccine-induced anti-HPV responses in previously
infected women were 12- to 26-times higher than those
occurring in women without prior infection.
A similar anamnestic response was observed after im-
munization of women with a single component (HPV 16
VLP) of the quadrivalent vaccine.33 Immunization produced
a marked increase in serum anti-HPV 16 L1 antibodies that
persisted for at least 1.5 years after the final dose. Women
who were baseline seronegative showed mean titers of
sL1Ab levels that were 36- to 78-fold higher than the
pre-immunization antibody titer observed in women who
had developed a natural immune response to HPV 16 in-
fection before enrollment. Further, serum anti-HPV 16 L1
antibodies in women who were baseline seropositive not
only increased faster than in women who were baseline
sero-negative but also peaked earlier and remained at
higher levels for a longer duration (Figure 3). Collectively,
these data suggest that HPV vaccines induce strong HPV
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Table 1 Anti-HPV 6, 11, 16, and 18 geometric mean titers (GMT) through 5 years (extension subjects only)
Vaccine recipients whowere baseline seronegative Placebo recipients whowere baseline seropositive
and PCR-negative for a specific HPV type * and PCR-negative for a specific HPV type *
N GMT 95% CI N GMT 95% CI
(mMU/ml) (mMU/ml)
Month 7
HPV-6 77 559.7 466.5, 671.5 9 31.3 14.9, 65.7
HPV-11 83 642.4 530.3, 778.2 2 342.7 N/A
HPV-16 78 3889.1 3147.1, 4806.1 9 42.0 13.8, 128.3
HPV-18 82 755.5 582.3, 980.1 7 36.4 12.3, 107.5
Month 36
HPV-6 77 88.1 70.5, 110.0 9 28.9 14.5, 57.6
HPV-11 79 78.0 61.5, 99.0 2 219.2 N/A
HPV-16 78 441.3 350.3, 556.1 9 21.5 <12, 64.3
HPV-18 82 50.5 36.7, 69.5 7 24.0 9.9, 58.0
Month 60
HPV-6 77 66.5 52.3, 84.6 9 30.5 14.9, 62.5
HPV-11 83 67.6 51.1, 89.3 2 150.4 N/A
HPV-16 78 395.4 303.2, 515.7 8 16.0 <12, 52.2
HPV-18 82 43.7 30.8, 62.1 7 32.7 9.3, 115.0
* Subjects in the per protocol population who were PCR-negative and seronegative to the relevant HPV type at day 1 and remained
PCR-negative to the same HPV type through month 60. Reproduced with permission from Villa LL et al Br J Cancer
2006;95:1459---1466.35
Figure 3 Geometric mean titers of serum anti-HPV 16 antibody levels (measured by competitive radioimmunoassay, cRIA) in women aged
18 to 26 years who received a 40 ug dose of HPV 16 VLP. Data show antibody response in women with and without undetectable serum
anti-HPV 16 L1 antibody at baseline. cRIA = competitive radioimmunoassay, GMT = geometric mean titer. , vaccinees with serum antibody
at baseline; •, vaccinees without serum antibody at baseline. Data reproduced with permission from Poland GA et al.33
responses that remain protective for many years --- perhaps
life-long.
Immune response in relation to age
HPV-specific antibodies have been used as a surrogate
marker to bridge efficacy from young women to pre-
adolescents. The immune response to a quadrivalent HPV
vaccine is inversely correlated with age, such that the
maximal response occurs in the pre-pubertal period. Pre-
adolescents mount an immune response that is stronger
than that seen in adults. Since the risk of HPV infection
is closely linked to sexual debut, which can be less than
13 years of age in many adolescents, it follows that the
greatest benefit from a prophylactic HPV vaccine would
occur if the vaccine were administered to prepubertal
children.
Cross-reacting antibodies
Evidence is emerging that the immune response to adminis-
tration of HPV vaccines generates anti-HPV antibodies that
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cross react with oncogenic HPV types other than HPV 16
and 18,34 including HPV 31 and 45, the third and fourth
most common types of HPV associated with cervical cancer.
However, the clinical significance of cross protection for
cervical lesions of any grade has not been established.
Long-term efficacy of vaccination (Nordic Cancer
Registry Extension)
The long-term safety and effectiveness of quadrivalent
HPV L1 VLP vaccine is currently being evaluated in collab-
oration with public health authorities in Denmark, Norway,
Iceland, and Sweden, which have well organized cancer
screening infrastructures and registries. Women in these
countries enrolled in the Phase III quadrivalent vaccine
studies will be followed through the cancer screening reg-
istries countries for at least 10 years. This sentinel cohort
will provide long-term follow-up data on the duration of
vaccine effectiveness.
Conclusions
The quadrivalent (HPV types 6, 11, 16, 18) vaccine protects
against HPV 16- and 18-related CIN 2/3 in young HPV-naïve
women and is efficacious against anogenital condylomata
(warts) and other genital neoplasias. The immunologic
profile of this vaccine has been well studied, with over
5 years of follow-up in young women and adolescents.
Its clinical efficacy appears to result from a marked and
sustained generation of neutralizing anti-HPV antibodies.
The immune response to a quadrivalent HPV vaccine is
inversely correlated with age, with the maximal response
occurring in prepubertal children (9 to 12 years). In light
of evidence showing persistence of these anti-HPV re-
sponses and demonstration of anamnestic responses, it
seems unlikely that booster immunization will be needed.
With 100% vaccine efficacy and no breakthrough HPV in-
fections due to waning immunity, an immune correlate
of long-term clinical efficacy and the minimum protective
anti-HPV level cannot be ascertained. However, long-term
follow-up studies in collaboration with the Nordic can-
cer registries are ongoing to assess the duration of HPV
protection.
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